Collecting blood samples to study food allergies

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to collect blood samples from individuals with peanut, tree nut, and other food allergies, as well as from healthy controls. The samples will be used to investigate the underlying mechanisms of food allergies and to enhance understanding of peanut and other allergens. Blood will be drawn and processed at various collaborating institutions, including the University of Colorado Denver and Massachusetts General Hospital. The study will also utilize de-identified serum and plasma from other sources to support its research objectives.

Why it matters

Who can join: the full rules

Inclusion Criteria:

This protocol is to draw blood for a variety of related studies of food allergy. For this reason, we will list each group of subjects and the inclusion criteria for that group.

1. De-identified sera or plasma from patients who have undergone Oral ImmunoTherapy (OIT) for peanut allergy. These samples already exist.

   * Inclusion criteria:

     1. patients have been enrolled in a controlled trial of OIT for peanuts, and had at least one oral challenge.
     2. Age 1-75.
2. De-identified samples from patients who are undergoing clinically indicated food challenges for peanut allergy.

   * Inclusion criteria:

     1. concern regarding possible allergy to peanuts,
     2. age 1-75,
     3. plan to undergo a clinically indicated challenge with peanuts.
3. Patients with peanut allergy.

   * Inclusion criteria:

     1. excellent history of a systemic reaction to peanuts,
     2. age 6-75.
4. Patients with other food allergies (especially tree nuts).

   * Inclusion criteria:

     1. excellent history of a systemic reaction to tree nuts or other foods,
     2. age 6-75.
5. Normal controls.

   * Inclusion criteria:

     1. no known food allergies,
     2. recent ingestion of peanuts without difficulty, and
     3. age 6-75.

Exclusion Criteria:

1. Any known significant medical or psychiatric diagnosis
2. Use of an investigational drug within 30 days
3. Use of omalizumab (anti-IgE; Xolair) within 6 months

Where it's running

• University of Colorado School of Medicine
  Denver, Colorado, United States Recruiting

Study contacts

• Principal investigator: Stephen Dreskin, MD, PhD — University of Colorado, Denver
• Study coordinator: Stephen Dreskin, MD, PhD
• Email: Stephen.Dreskin@ucdenver.edu
• Phone: 303-724-7190

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• LCA-0061 dose-ranging safety study for people with allergies

  This Phase 1 study tests whether different single and multiple doses of LCA-0061 are safe and tolerable in people with atopy or peanut allergy, compared with placebo.

  Recruiting Phase 1 Lycia Therapeutics, Inc. · Mississauga, Ontario · NCT07701954

• Long-term follow-up after 18 months of oral immunotherapy for peanut, egg, or milk allergy (5–15 years later)

  This follow-up will see if children and young people who completed an 18-month oral immunotherapy for peanut, egg, or milk allergy still have changes in allergy tests and better quality of life 5–15 years later.

  Recruiting Murdoch Childrens Research Institute · Parkville, Victoria · NCT07359183

• MY006 to prevent severe allergic reactions from peanut exposure

  MY006 injections will be tested to see if they prevent severe allergic reactions in adults and adolescents with peanut allergy.

  Recruiting at 8 sites Phase 1 Mabylon AG · Little Rock, Arkansas and 8 other locations · NCT07287033

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.